A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas

Impairment of stress granule assembly via inhibition of the eIF2alpha phosphorylation sensitizes glioma cells to chemotherapeutic agents

(2016) Fabrício de Almeida Souza Vilas-Boas et al.   JOURNAL OF NEURO-ONCOLOGY

A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas

(2015) Yazmín Odia et al.   JOURNAL OF NEURO-ONCOLOGY

Bortezomib-Induced Unfolded Protein Response Increases Oncolytic HSV-1 Replication Resulting in Synergistic Antitumor Effects

(2014) J. Y. Yoo et al.   CLINICAL CANCER RESEARCH

Bortezomib Downregulates MGMT Expression in T98G Glioblastoma Cells

(2013) Panagiotis J. Vlachostergios et al.   CELLULAR AND MOLECULAR NEUROBIOLOGY

Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial

(2013) Mark R. Gilbert et al.   JOURNAL OF CLINICAL ONCOLOGY

Cellular stress response and innate immune signaling: integrating pathways in host defense and inflammation

(2013) Sujatha Muralidharan et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma

(2013) Rong Bu et al.   LEUKEMIA & LYMPHOMA

A phase I study of bortezomib and temozolomide in patients with advanced solid tumors

(2011) J. Portnow et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives

(2011) D. Chen et al.   CURRENT CANCER DRUG TARGETS

Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study

(2011) B. B. Friday et al.   NEURO-ONCOLOGY

Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma

(2010) Donna E. Reece et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study

(2010) James R. Perry et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma

(2010) Surasak Phuphanich et al.   JOURNAL OF NEURO-ONCOLOGY

NFKBIADeletion in Glioblastomas

(2010) Markus Bredel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Mechanisms of proteasome inhibitor action and resistance in cancer

(2008) David J. McConkey et al.   DRUG RESISTANCE UPDATES

Phase I Trial Using Proteasome Inhibitor Bortezomib and Concurrent Temozolomide and Radiotherapy for Central Nervous System Malignancies

(2008) Gregory J. Kubicek et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

New (alternative) temozolomide regimens for the treatment of glioma

(2008) Wolfgang Wick et al.   NEURO-ONCOLOGY